Watch this session exploring the rapidly evolving landscape of pharmaceutical pricing and compliance. This webinar will demystify the Most Favored Nation (MFN) pricing model, Direct‑to‑Consumer (DTC) strategies, and the GENEROUS framework, highlighting their growing influence on U.S. and global drug pricing.

This session provides a practical overview of MFN pricing mechanics—including international reference pricing and Medicaid GNUP agreements—alongside emerging DTC strategies and their compliance considerations. We’ll also break down the GENEROUS framework and how it shapes manufacturer approaches to discounting, rebates, and governance.  

In addition, we’ll explore how Model N automates key compliance workflows, streamlines operational processes, and ensures alignment across complex policy environments. Manufacturers and stakeholders will gain actionable steps to strengthen governance, prepare for future policy shifts, and operate with greater confidence in an era of intensifying scrutiny. 

What You’ll Learn: 

• Key MFN, DTC, and GENEROUS requirements and their impact on drug pricing and compliance.  
• Essentials of global and U.S. pricing frameworks, including GNUP and IRP.  
• How Model N automates compliance and operational workflows.  
• Practical guidance to strengthen governance and prepare for upcoming policy changes.
• The policy mechanics behind MFN pricing, including international reference pricing and GNUP agreements.
• DTC trends and how they intersect with regulatory and compliance expectations.
• How the GENEROUS model influences manufacturer strategies, discounting, and rebate processes.
• Ways Model N supports operational excellence through automation and regulatory alignment

Presented By

Michael Grosberg

VP, Product Management

Model N

Manish Kumar

Sr. Director, Product Management

Model N